Introduction/Background*Sentinel node is a very powerful tool in endometrial cancer, giving information on nodal status involvement, with low morbidity. Within a few years, it became part of the standard treatment, at least for low and intermediate-risk patients. Its implementation, safety and reliability, and the evolution of the patient have to be monitored to confirm its great added value and its place in the standard of care for endometrial cancer

Methodology We performed a multicenter retrospective review of all endometrial cancer cases in which SN procedures (with/without pelvic and paraaortic lymphadenectomy) was planned to be performed, from the centers of the gynecological oncology group (ONCO-GF) of the Gynecology and Obstetrics association, french speaking part in Belgium (CR-GOLFB). Academic and non-academic hospitals participate. The study was accepted by the Ethical Committee of the coordinating center of the study (Cliniques Universitaires St Luc) and registered on clinicltrial.gov (NCT02545348).

Result(s)*To date, 233 patients were included in the study but some center have still to send a part of their data. Preliminary data show that 96% of the surgery we performed by minimally invasive approach. Overall detection rate is 90% but only 69% of bilateral detection. Regarding the tracer, the best bilateral detection rate was obtained with Indocyanine green (84%). With the methylene blue alone, no detection occurs in 22% of cases. In a preliminary pathological analysis of the sentinel node, 17% of SN were infiltrated, 8% with macro metastasis, 2% of micro metastasis, and 8% isolated tumor cells (ITC). We did not record any major intraoperative complication, but one late post-operative dead, in a patient with complete pelvic and para-aortic lymphadenectomy with a duodenal breach that leads to late aortic-duodenal fistula.

Conclusion*Our preliminary data show a very good detection rate of 96%, even if bilateral detection was only 69%, in a group of patients from academic and non-academic centers. Learning curves and the evolution of the patient must still be evaluated. The complete data will be presented at the congress.